ISACA Releases New Report on Privacy Trends, Obstacles and Predictions Ahead of Data Privacy Day
26.1.2021 19:16:00 EET | Business Wire | Press release
As Data Privacy Day approaches this week, ISACA has released a new survey report, Privacy in Practice 2021: Data Privacy Trends, Forecasts and Challenges, exploring past and future trends in privacy by design, privacy obstacles and privacy workforce.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210126005846/en/
The current privacy landscape is rife with low investment, lack of high-level prioritization and lack of skilled privacy professionals that leave organizations open to penalties and loss of reputation. ISACA, a global professional association and learning organization, surveyed more than 1,800 IT audit, risk, security and privacy professionals on privacy workforce trends and skills gaps, privacy programs, and the regulations and frameworks that guide privacy programs. (Graphic: Business Wire)
Privacy by Design
Enterprises that report they always use privacy by design are more likely to be driven by a combination of compliance and ethics (62 percent vs. 52 percent total). They are also nearly two-and-a-half times more likely to be completely confident in their privacy team’s ability to ensure data privacy and achieve compliance with new privacy laws and regulations (24 percent vs. 10 percent total). However, there was not a meaningful difference in the number of privacy breaches they experienced in the last 12 months compared to all respondents. Approximately 10 percent of both groups reported breaches—a potentially underreported number.
Privacy Obstacles
Respondents identified other common privacy failures, including:
- Lack of training or poor training (64 percent)
- Failure to perform a risk analysis (53 percent)
- Bad or nonexistent detection of personal information (50 percent)
Respondents cited privacy principles frameworks, experience-based credentials and privacy training as the most helpful methods in overcoming these obstacles.
Workforce Trends
Respondents indicated that they foresee an increased demand for technical privacy roles compared to legal/compliance roles (70 percent increase vs. 59 percent increase). However, technical privacy roles were more likely to be considered understaffed (46 percent vs. 33 percent).
Nevertheless, hiring managers have been filling these roles through training—47 percent noted they have been training non-privacy staff interested in moving into privacy roles. Ninety-two percent of respondents indicated that they have privacy staff who started their career in IT or security and moved into privacy and compliance.
“Organizations will continue needing a strong privacy workforce in the years ahead,” says Nader Qaimari, ISACA chief product officer. “As non-privacy professionals increasingly get opportunities to train for this career path and gain technical skills, it not only eases the privacy skills gap but enriches this workforce.”
The complimentary webinar, “Exploring Privacy Trends, Challenges & Predictions,” on 28 January 2021 at 12:00 PM EST / 5:00 PM (UTC) will explore the survey highlights. To learn more, visit www.isaca.org/education/online-events/lms_w012821.
Access the Privacy in Practice 2021 survey report at www.isaca.org/privacy-in-practice-2021. Learn more about ISACA’s privacy resources, including the Certified Data Privacy Solutions Engineer™ (CDPSE™) certification, at www.isaca.org/cdpse.
About ISACA
For more than 50 years, ISACA® (www.isaca.org) has equipped individuals with knowledge, credentials, education and community to progress their careers and transform their organizations, and enables enterprises to train and build quality teams. ISACA leverages the expertise of more than 150,000 members who work in information security, governance, assurance, risk and privacy to drive innovation through technology. Its presence in 188 countries includes more than 220 chapters.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210126005846/en/
Contact information
Emily Van Camp, +1.847.385.7217, communications@isaca.org
Kristen Kessinger, +1.847.660.5512, kkessinger@isaca.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 10:00:00 EEST | Press release
SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter timeframes. The MoU underscores growing market adoption of SWISSto12’s HummingLink payload technology that leverages 3D-printing, with more than 2,000 pr
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 10:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly effective oral therapies that also address the diverse and often challenging manifestations of psoriasis, including involvement of high-impact sites like the scalp,” said Andy Plump, M.D., Ph.D., president of R&D at Takeda. “Our Phase 3 data demonstrated rapid and durable skin clearance across various patient types and in high-impact and hard-to-treat areas. Based on the results across nearly 3,000 patients, zaso
Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 10:00:00 EEST | Press release
According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, today announced the launch of Luna 8, its next-generation hardware security module. Designed for the transition to post-quantum cryptography, Luna 8 enables organizations to securely store, protect, and manage cryptographic keys with market-leading performance, scalability, and speed. As organizations face growing pressure from emerging quantum threats, expanding AI workloads and evolving stringent regulatory requirements, Luna 8 provides the performance, security and cryp
Focused Support Launches Cavok STRIKE to Expand Link-16 Participation Across the Joint Force14.9.2026 08:00:00 EEST | Press release
Focused Support LLC today announced the launch of Cavok STRIKE, an integrated software capability that expands the Link-16 tactical battlespace picture by enabling additional operational platforms to participate in the Link-16 network. Modern battlefields have increasing numbers of unmanned systems, sensors, and supporting platforms operating throughout the joint battlespace. The rapid proliferation of Group 1, 2, and 3 UAS, including both expendable and recoverable systems, has created a growing need to integrate these assets into the broader tactical network. Many of these platforms provide operationally relevant information but have historically remained outside the Link-16 network due to limitations in size, weight, power, platform integration complexity, or acquisition cost. Cavok STRIKE addresses this gap by enabling platforms to participate in the Link-16 network as non-command-and-control participants. This allows those platforms to interoperate with traditional Link-16 platfor
Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma14.9.2026 08:00:00 EEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use on the fully automated LUMIPULSE® G immunoassay platform in Brazil. “ANVISA authorization of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays marks another important step in our mission to expand access to reliable, clinically meaningful blood-based biomarkers for clinicians and patients worldwide,” said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “By making both neurological biomarker assays available to laboratories on a single, fully automated platform, we are helping support more informed clinical decision-making across a broad range of neurological conditions and throughout the diagnostic pathway.” The Brazilian ANVISA authorizations are based on the already CE marked in vitro diagnostics (IVD) approvals of these two
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
